

 **BLENREP**
belantamab
mafodotin-blmf
for injection 70 mg

I want to be a

come back kid

Christopher

BLENREP may help power a comeback to remission if his multiple myeloma returns

Not an actual patient.

In adults with multiple myeloma whose cancer returned or did not respond after 2 or more prior treatments, including a proteasome inhibitor and an immunomodulatory agent,

**BLENREP COMBINATION
HELPED KEEP MULTIPLE MYELOMA IN
REMISSION 3X LONGER^{*†}**

Based on how the data was analyzed, the meaning of these results may be limited. Talk to your doctor about whether BLENREP may be right for you.

^{*}Remission here refers to progression-free survival, the average length of time after the start of treatment in which a person is alive and their cancer does not get worse.

[†]In a clinical study named DREAMM-7, people taking the BLENREP + bortezomib + dexamethasone combination stayed in remission for a median of 31 months, compared to 10 months with the daratumumab + bortezomib + dexamethasone combination. Individual results may vary.

Approved Use

BLENREP is a prescription medicine used in combination with the medicines bortezomib and dexamethasone to treat adults with multiple myeloma who:

- have received at least 2 prior treatments, including a proteasome inhibitor and an immunomodulatory agent, and
- their cancer has come back or did not respond to prior treatment

It is not known if BLENREP is safe and effective in children.

Please see additional Important Safety Information throughout. Click to see the full Prescribing Information, including Boxed Warning and Medication Guide for BLENREP.

Important Safety Information

What is the most important information I should know about BLENREP?


BLENREP can cause serious side effects, including:

- **Eye problems.** Eye problems are common with BLENREP and can also be severe. BLENREP can cause changes to the surface of your eye, which can lead to symptoms of eye problems, including:
 - decreased vision
 - blurred vision
 - dry eyes
 - sensitivity to light
 - feeling like something is in your eyes
 - eye irritation
 - eye pain

It's common for people with multiple myeloma to have their disease return or to stop responding to treatment over time

You and your care team can work together to choose a therapy with the goal of slowing progression and extending remission

US incidence and prevalence statistics



36,110
NEW CASES

of multiple myeloma are expected to be diagnosed in the US in 2025



168,234
PEOPLE

are living with multiple myeloma

MULTIPLE MYELOMA IS THE
2ND

SECOND MOST
COMMON

form of blood cancer

BLENREP is a targeted treatment that works in multiple ways

How BLENREP works


BLENREP binds to a protein found on the surface of myeloma cells called BCMA

BLENREP KILLS MYELOMA CELLS

by delivering the anti-cancer medicine into the cell

BLENREP TRIGGERS THE IMMUNE SYSTEM

as another way to kill multiple myeloma cells



BCMA is found at higher levels on myeloma cells. BLENREP can affect normal cells.

Approved Use

BLENREP is a prescription medicine used in combination with the medicines bortezomib and dexamethasone to treat adults with multiple myeloma who:

- have received at least 2 prior treatments, including a proteasome inhibitor and an immunomodulatory agent, and
 - their cancer has come back or did not respond to prior treatment
- It is not known if BLENREP is safe and effective in children.

Important Safety Information for BLENREP (cont'd)

Ulcers on the surface of the eye (corneal ulcers), including with infection, may also happen during treatment with BLENREP.

Tell your healthcare provider right away if you notice any new or worsening eye symptoms or vision changes during treatment with BLENREP.

Please see additional Important Safety Information throughout. Click to see the full Prescribing Information, including Boxed Warning and Medication Guide for BLENREP.

BLENREP
belantamab
mafodotin-blmf
for injection 70 mg

DREAMM-7 measured how long people stayed in remission

How BLENREP was studied

DREAMM-7 was a global, randomized clinical study that included people with multiple myeloma who had:

- Previously taken 2 or more multiple myeloma treatments, including a proteasome inhibitor and immunomodulatory agent
- Experienced disease progression while taking, or after, their most recent treatment

DREAMM-7 measured time in remission with a BLENREP combination, compared with another common treatment combination that included daratumumab.

- Remission here refers to the median length of time after the start of treatment in which a person is alive and their cancer does not get worse

Other goals of the study included:

- Overall survival
- Overall response rate

Study participants



DREAMM-7 included 217 people who were split into 2 groups and given 1 of the 2 treatment combinations described below:

- 108 people were given BLENREP + bortezomib + dexamethasone
- 109 people were given daratumumab + bortezomib + dexamethasone

Henry
BLENREP may help power a comeback to remission if his multiple myeloma returns



Not an actual patient.


Important Safety Information for BLENREP (cont'd)

Your healthcare provider will refer you to an eye care specialist (such as an ophthalmologist or optometrist) to check your eyes before you start treatment, before you receive each dose of BLENREP, and as needed for any new or worsening eye problems. **It is important that you:**

- Keep all of your eye care appointments because some changes can happen without symptoms and may only be seen on an eye exam
- Use preservative-free artificial tears at least 4 times per day starting with your first infusion and continuing until the end of treatment with BLENREP

The BLENREP combination provided 3x longer remission

People taking the BLENREP combination stayed in remission for a median of 31 months, compared to 10 months with the daratumumab combination



3X

LONGER REMISSION: MEDIAN DIFFERENCE OF 21 MONTHS

Based on how the data was analyzed, the meaning of these results may be limited.

Talk to your doctor about whether BLENREP may be right for you. Individual results may vary.


Median is the middle number in a set of data, where half of the people had longer results than this middle number and half had shorter.

Important Safety Information for BLENREP (cont'd)

- Avoid wearing contact lenses during treatment with BLENREP unless directed by your eye care specialist
- Use caution when driving or operating machinery because BLENREP may cause changes to your vision

Because of the risk of eye problems, BLENREP is available only through a restricted program called the BLENREP Risk Evaluation and Mitigation Strategy (REMS). Your healthcare provider will give you the BLENREP REMS Patient Guide, which describes the risk of eye problems, and will explain the REMS program to you. To receive BLENREP, you must enroll in the REMS program and receive eye exams during treatment. See **“What are the possible side effects of BLENREP?”** for more information about side effects.

Please see additional Important Safety Information throughout. Click to see the full [Prescribing Information](#), including [Boxed Warning](#) and [Medication Guide](#) for BLENREP.




Most people responded to the BLENREP combination

Overall response rate

82%

- 82% of people (88 out of 108) responded to the BLENREP combination*
- 57% of people (62 out of 109) responded to the daratumumab combination*



*Due to rounding, exact totals are 1% higher (83% and 58%).

Based on how the data was analyzed, the meaning of these results may be limited.

Overall response rate is the total percentage of patients who responded with a partial response or better.

Stringent complete response is the highest level of response, with no detectable cancer cells found in the bone marrow.[†]

Complete response means the cancer cells cannot be detected in blood or urine tests and there are fewer than 5% myeloma cells in the bone marrow.[†]

Very good partial response is when there’s a big reduction in cancer cells, with at least 90% of the cancer cells gone from the blood and urine.

Partial response means the cancer cells level is at least 50% lower than it was before treatment.

[†]This does not mean the disease has been cured.

Important Safety Information for BLENREP (cont’d)

What are the possible side effects of BLENREP?

BLENREP can cause serious side effects, including:

- See “Eye Problems” in “What is the most important information I should know about BLENREP?”
- **Decrease in platelets (thrombocytopenia)** is common with BLENREP and can also be severe. Platelets are a type of blood cell that help your blood to clot. Your healthcare provider will check your blood cell counts before you start treatment with BLENREP and during treatment as needed. Tell your healthcare provider if you get any bleeding or bruising during treatment with BLENREP

More people on the BLENREP combination lived longer

Overall survival

Overall survival refers to the length of time people were still alive from when they were randomly assigned to a treatment group.

69%

of people (75 out of 108) taking the BLENREP combination were alive at the time of analysis.

69% of people (75 out of 108) taking BLENREP combination were alive at the time of analysis.

48% of people (52 out of 109) taking daratumumab combination were alive at the time of analysis.

Median overall survival was not yet reached.[‡]

Median overall survival was reached at 36 months.[‡]

Median is the middle number in a set of data. Reaching the median means that half the people lived longer than this middle number, and half did not.

[‡]These percentages include people who were still alive but left the trial for any reason and people who continued to be followed if they stayed in the trial.

Based on how the data was analyzed, the meaning of these results may be limited.

Talk to your doctor about whether BLENREP may be right for you. Individual results may vary.

Important Safety Information for BLENREP (cont’d)

The most common side effects of BLENREP when given with bortezomib and dexamethasone include:

- See “Eye problems” in “What is the most important information I should know about BLENREP?”
- upper respiratory tract infection
- liver problems
- diarrhea
- tiredness
- pneumonia
- cataract
- COVID-19

Please see additional Important Safety Information throughout. Click to see the full Prescribing Information, including Boxed Warning and Medication Guide for BLENREP.

BLENREP
belantamab
mafodotin-blmf
for injection 70 mg

Susan
BLENREP may help power a comeback to remission if her multiple myeloma returns

Not an actual patient.

Side effects of BLENREP



The most important information you should know about BLENREP

BLENREP can cause serious side effects, including:

- **Eye problems**, which are common with BLENREP and can also be severe. BLENREP can cause changes to the surface of your eye, which can lead to symptoms of eye problems, including:
 - decreased vision
 - blurred vision
 - dry eyes
 - sensitivity to light
 - feeling like something is in your eyes
 - eye irritation
 - eye pain

Ulcers on the surface of the eye (corneal ulcers), including with infection, may also happen during treatment with BLENREP.

Tell your healthcare provider right away if you notice any new or worsening eye symptoms or vision changes during treatment with BLENREP.

Your healthcare provider will refer you to an eye doctor (such as an ophthalmologist or optometrist) to check your eyes before you start treatment, before you receive each dose of BLENREP, and as needed for any new or worsening eye problems. **It is important that you:**

- Keep all of your eye care appointments because some changes can happen without symptoms and may only be seen on an eye exam
- Use preservative-free artificial tears at least 4 times per day starting with your first infusion and continuing until the end of treatment with BLENREP
- Avoid wearing contact lenses during treatment with BLENREP unless directed by your eye doctor
- Use caution when driving or operating machinery because BLENREP may cause changes to your vision

Because of the risk of eye problems, BLENREP is available only through a restricted program called the BLENREP Risk Evaluation and Mitigation Strategy (REMS). Your healthcare provider will give you the BLENREP REMS Patient Guide, which describes the risk of eye problems, and will explain the REMS program to you. To receive BLENREP, you must enroll in the REMS program and receive eye exams during treatment.



Additional serious side effects can include

- **Decrease in platelets (thrombocytopenia)** is common with BLENREP and can also be severe. Platelets are a type of blood cell that help your blood to clot. Your healthcare provider will check your blood cell counts before you start treatment with BLENREP and during treatment as needed. Tell your healthcare provider if you get any bleeding or bruising during treatment with BLENREP



In addition to eye problems, the most common side effects of BLENREP when given with bortezomib and dexamethasone include:

- upper respiratory tract infection
- liver problems
- tiredness
- cataract
- diarrhea
- pneumonia
- COVID-19

The most common severe abnormal blood test results during treatment with BLENREP include decreases in platelets, white blood cells, and hemoglobin, and increases in certain liver enzymes.

Tell your healthcare provider right away if you get new or worsening unexplained signs or symptoms of lung problems, including shortness of breath, chest pain, or cough.

Your healthcare provider may decrease your dose, temporarily stop, or completely stop treatment with BLENREP if you get serious side effects.

BLENREP may affect fertility in males and females, which may affect your ability to have children. Talk to your healthcare provider if this is a concern for you.

These are not all of the possible side effects of BLENREP.

Eye problems such as changes in vision are common with BLENREP

Changes in vision with BLENREP were measured by the eye chart exam known as the Best-Corrected Visual Acuity (BCVA) test.

In DREAMM-7, nearly all of the people (89%) who were treated with the BLENREP combination had a reduction in BCVA in at least 1 eye. This means their vision was less sharp even with corrective lenses.

For people who experienced a reduction in BCVA in at least 1 eye



Images are for illustrative purposes only. Vision will differ for each individual. Images created with an Eye Care Professional.

Talk to your doctor to learn more about changes in vision while taking BLENREP

Please see Important Safety Information throughout. Click to see the full [Prescribing Information](#), including Boxed Warning and [Medication Guide](#) for BLENREP.

BLENREP
belantamab
mafodotin-blmf
for injection 70 mg

What to expect when you start BLENREP



~30-minute infusion

BLENREP will be given to you through an intravenous (IV) infusion at a REMS-certified outpatient site, such as your doctor's office or an outpatient clinic. Timing will vary by patient, but can be as short as 30 minutes. **No hospitalization is needed to start treatment with BLENREP.**



Dosing schedule and blood monitoring

BLENREP is usually given **every 3 weeks**, in combination with bortezomib and dexamethasone for the first 8 cycles, then treatment continues with BLENREP alone. Your healthcare provider will decide how many treatments you will need, and will check your blood cell counts before you start treatment with BLENREP, and during treatment as needed.



Eye exams required before each dose

Eye exams are required before starting BLENREP, then repeated before each dose. Additional eye exams will also be needed for new or worsening symptoms or as your doctor recommends. This will help your healthcare provider determine if a change in dose is required.

Important Safety Information for BLENREP (cont'd)

The most common severe abnormal blood test results during treatment with BLENREP include decreases in platelets, white blood cells, and hemoglobin, and increases in certain liver enzymes.

Tell your healthcare provider right away if you get new or worsening unexplained signs or symptoms of lung problems, including shortness of breath, chest pain, or cough.

Your healthcare provider may decrease your dose, temporarily stop, or completely stop treatment with BLENREP if you get serious side effects.

BLENREP may affect fertility in males and females, which may affect your ability to have children. Talk to your healthcare provider if this is a concern for you.

These are not all of the possible side effects of BLENREP.

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Before receiving BLENREP, tell your healthcare provider about all of your medical conditions, including if you:

- have or had vision or eye problems
- have or had bleeding problems
- are pregnant or plan to become pregnant. BLENREP can harm your unborn baby



An eye doctor will check your eyes before each of your BLENREP doses

Your eye doctor will perform 2 common eye exams during your visits



Eye chart exam known as Best-Corrected Visual Acuity test

It measures how sharp your eyesight is, usually by reading an eye chart from a distance.



Eye exam known as a slit lamp test

An eye doctor takes a closer look at the front and inside of your eye.

If you have side effects, your oncologist may adjust your dose

- Adjustments may include an increase in time between doses or a decrease in dose
- If you experience serious side effects, your oncologist may temporarily or completely stop treatment with BLENREP
- If you miss any appointments, call your healthcare provider as soon as possible to reschedule your appointment

Talk to your doctor for medical advice about side effects.

Important Safety Information for BLENREP (cont'd)

Females who are able to become pregnant:

- Your healthcare provider will do a pregnancy test before you start treatment with BLENREP
- Use effective birth control during treatment with BLENREP and for 4 months after the last dose. Talk to your healthcare provider about birth control methods you can use during this time
- Tell your healthcare provider if you become pregnant or think you may be pregnant during treatment with BLENREP

Males with female partners who are able to become pregnant:

- Use effective birth control during treatment with BLENREP and for 6 months after the last dose
- are breastfeeding or plan to breastfeed. It is not known if BLENREP passes into your breast milk. Do not breastfeed during treatment with BLENREP and for 3 months after the last dose

Please see additional Important Safety Information throughout. Click to see the full [Prescribing Information](#), including [Boxed Warning](#) and [Medication Guide](#) for BLENREP.

BLENREP
belantamab
mafodotin-blmf
for injection 70 mg

The Together with BLENREP program is support made just for you

Together with BLENREP is designed to support patients like you during treatment with BLENREP.

It's more than a program—it's our promise to understand your needs, listen to what's important to you, and create meaningful connections along the way.

For patients prescribed BLENREP, Together with BLENREP offers personalized help to get you started and stay informed.

Key program features include:

- Coverage support: Insurance and coverage information to you and your doctor, including supporting your doctor if you face coverage challenges
- Cost support: Help make paying for BLENREP more manageable with options tailored to your needs
- Patient Support: A dedicated Nurse Navigator* through key steps in your treatment journey by helping you:
 - Understand your insurance coverage
 - Find an eye care professional (ECP) for required eye exams
 - Receive education about BLENREP and multiple myeloma

You can enroll in 2 ways:

- Visit www.togetherwithGSK.com/blenrep/patient/ to start your enrollment online; or
- Enroll by downloading this form and work with your doctor to fill it out at your next doctor's visit for them to submit

*The Nurse Navigator does not provide medical advice and is not a part of your doctor's care team. Please ask your doctor any questions that you might have about your disease and treatment with BLENREP.



Coverage Support:

Once you sign up for Together with BLENREP, your dedicated Nurse Navigator will have your insurance coverage checked and help you understand your benefits. The information provided by Together with BLENREP is not a guarantee of coverage or payment.

- Your dedicated Nurse Navigator can help with:
 - Explaining your insurance coverage for BLENREP†
 - Confirming if your insurance covers the infusion site that your doctor selects
 - Confirming if your medical insurance will cover your eye exams required for BLENREP treatment
 - Working through any insurance changes you may have to avoid treatment interruption due to coverage changes

†There may be current coverage restrictions or requirements that may apply; be sure to contact your plan for more information. The information provided by Together with BLENREP is not a guarantee of coverage.



Cost Support:

Along with your existing insurance, your dedicated Nurse Navigator can give you information on additional programs that may help you pay for BLENREP:

- BLENREP Copay Assistance Program: May help eligible patients with commercial insurance by providing assistance with out-of-pocket medication costs
- BLENREP Patient Assistance Program: Offers medicine at no cost to eligible patients. Operated by the GSK Patient Access Programs Foundation, an independent non-profit organization separate from GSK
- Foundation Programs: Information on independent third-party foundations separate from GSK that may help eligible patients with out-of-pocket costs‡

‡Together with BLENREP cannot guarantee that you will be eligible for assistance from a foundation, as each foundation has their own rules on eligibility which are subject to change.



Patient Support:

Once you sign up for Together with BLENREP, your dedicated Nurse Navigator* can help you, your oncologist's office, and your eyecare provider (ECP)'s office work together during your treatment journey with BLENREP by:

- Empowering you with education and resources, helping you with insurance questions, helping you find an ECP if you don't already have one, and reminding you to schedule eye exams
- Helping your oncologist's office understand your insurance, share your ECP's contact information, and reinforcing the importance of eye exam results before BLENREP treatment
- Helping your ECP's office understand BLENREP treatment requirements, coverage for eye exams, and the importance of the sharing of eye exam results with your oncologist's office before BLENREP treatment

To learn more about Together with BLENREP and enroll, [click here](#)



Please see Important Safety Information throughout. Click to see the full [Prescribing Information](#), including [Boxed Warning](#) and [Medication Guide](#) for BLENREP.

BLENREP
belantamab
mafodotin-blmf
for injection 70 mg

Important Safety Information for BLENREP

What is the most important information I should know about BLENREP?

BLENREP can cause serious side effects, including:

- **Eye problems.** Eye problems are common with BLENREP and can also be severe. BLENREP can cause changes to the surface of your eye, which can lead to symptoms of eye problems, including:
 - decreased vision
 - dry eyes
 - feeling like something is in your eyes
 - eye irritation
 - blurred vision
 - sensitivity to light
 - eye pain

Ulcers on the surface of the eye (corneal ulcers), including with infection, may also happen during treatment with BLENREP.

Tell your healthcare provider right away if you notice any new or worsening eye symptoms or vision changes during treatment with BLENREP.

Your healthcare provider will refer you to an eye care specialist (such as an ophthalmologist or optometrist) to check your eyes before you start treatment, before you receive each dose of BLENREP, and as needed for any new or worsening eye problems. **It is important that you:**

- Keep all of your eye care appointments because some changes can happen without symptoms and may only be seen on an eye exam
- Use preservative-free artificial tears at least 4 times per day starting with your first infusion and continuing until the end of treatment with BLENREP
- Avoid wearing contact lenses during treatment with BLENREP unless directed by your eye care specialist
- Use caution when driving or operating machinery because BLENREP may cause changes to your vision

Because of the risk of eye problems, BLENREP is available only through a restricted program called the BLENREP Risk Evaluation and Mitigation Strategy (REMS). Your healthcare provider will give you the BLENREP REMS Patient Guide, which describes the risk of eye problems, and will explain the REMS program to you. To receive BLENREP, you must enroll in the REMS program and receive eye exams during treatment. See **“What are the possible side effects of BLENREP?”** for more information about side effects.

What are the possible side effects of BLENREP?

BLENREP can cause serious side effects, including:

- **See “Eye Problems” in “What is the most important information I should know about BLENREP?”**
- **Decrease in platelets (thrombocytopenia)** is common with BLENREP and can also be severe. Platelets are a type of blood cell that help your blood to clot. Your healthcare provider will check your blood cell counts before you start treatment with BLENREP and during treatment as needed. Tell your healthcare provider if you get any bleeding or bruising during treatment with BLENREP

The most common side effects of BLENREP when given with bortezomib and dexamethasone include:

- See **“Eye Problems” in “What is the most important information I should know about BLENREP?”**
- upper respiratory tract infection
- liver problems
- diarrhea
- tiredness
- pneumonia
- cataract
- COVID-19

The most common severe abnormal blood test results during treatment with BLENREP include decreases in platelets, white blood cells, and hemoglobin, and increases in certain liver enzymes.

Tell your healthcare provider right away if you get new or worsening unexplained signs or symptoms of lung problems, including shortness of breath, chest pain, or cough.

Your healthcare provider may decrease your dose, temporarily stop, or completely stop treatment with BLENREP if you get serious side effects.

BLENREP may affect fertility in males and females, which may affect your ability to have children. Talk to your healthcare provider if this is a concern for you.

These are not all of the possible side effects of BLENREP.

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Before receiving BLENREP, tell your healthcare provider about all of your medical conditions, including if you:

- have or had vision or eye problems
- have or had bleeding problems
- are pregnant or plan to become pregnant. BLENREP can harm your unborn baby

Females who are able to become pregnant:

- Your healthcare provider will do a pregnancy test before you start treatment with BLENREP
- Use effective birth control during treatment with BLENREP and for 4 months after the last dose. Talk to your healthcare provider about birth control methods you can use during this time
- Tell your healthcare provider if you become pregnant or think you may be pregnant during treatment with BLENREP

Males with female partners who are able to become pregnant:

- Use effective birth control during treatment with BLENREP and for 6 months after the last dose
- are breastfeeding or plan to breastfeed. It is not known if BLENREP passes into your breast milk. Do not breastfeed during treatment with BLENREP and for 3 months after the last dose

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088. You may also report negative side effects to GSK at gsk.public.reportum.com or 1-888-825-5249.





Hilary
BLENREP may help power
a comeback to remission if her
multiple myeloma returns

Not an actual patient.

Ask your oncologist if BLENREP may be right for you

- In DREAMM-7, the **BLENREP combination provided 3x longer remission** than the daratumumab combination—a median of 31 months with the BLENREP combination vs 10 months with the daratumumab combination. **82% of people responded to the BLENREP combination** vs 57% who responded to the daratumumab combination
- **Eye problems with BLENREP are common and can be severe**, including changes to the surface of your eyes that can lead to symptoms of eye problems and vision changes. Some eye changes can happen without symptoms and may only be seen on an eye exam, **so it is important to keep all of your eye care appointments**
- Because of the risk of eye problems, **BLENREP is available only through a restricted program called the BLENREP REMS**. To receive BLENREP, you must enroll in the REMS program and receive eye exams during treatment
- Your healthcare provider may **decrease your dose, temporarily stop, or completely stop treatment with BLENREP** if you get serious side effects
- In addition to eye problems, **the other possible side effects of the BLENREP combination include** decrease in platelets, upper respiratory tract infection, liver problems, diarrhea, tiredness, pneumonia, cataract, and COVID-19
- **Treatment is a ~30-minute infusion, usually starting every 3 weeks**, given at a REMS-certified site such as your doctor's office or an outpatient clinic. Timing varies by patient

To learn more, talk to your doctor
or visit [BLENREP.com](https://www.blenrep.com)

Important Safety Information for BLENREP (cont'd)

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

You are encouraged to report negative side effects of prescription drugs to the FDA.

Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

You may also report negative side effects to GSK at gsk.public.reportum.com or 1-888-825-5249.

Please see additional Important Safety Information throughout.
Click to see the full [Prescribing Information](#), including
Boxed Warning and [Medication Guide](#) for BLENREP.

BLENREP
belantamab
mafodotin-blmf
for injection 70 mg

I want to be a

come back kid

ASK YOUR ONCOLOGIST
IF BLENREP CAN
HELP POWER
YOUR COMEBACK

Maria

BLENREP may help
power a comeback to
remission if her multiple
myeloma returns

Not an actual patient.

TO LEARN MORE,
VISIT [BLENREP.COM](https://www.blenrep.com)

Approved Use

BLENREP is a prescription medicine used in combination with the medicines bortezomib and dexamethasone to treat adults with multiple myeloma who:

- have received at least 2 prior treatments, including a proteasome inhibitor and an immunomodulatory agent, and
- their cancer has come back or did not respond to prior treatment

It is not known if BLENREP is safe and effective in children.

Please see additional Important Safety Information throughout. Click to see the full Prescribing Information, including Boxed Warning and [Medication Guide](#) for BLENREP.

Important Safety Information

What is the most important information I should know about BLENREP?

BLENREP can cause serious side effects, including:

- **Eye problems.** Eye problems are common with BLENREP and can also be severe. BLENREP can cause changes to the surface of your eye, which can lead to symptoms of eye problems, including:
 - decreased vision
 - blurred vision
 - dry eyes
 - sensitivity to light
 - feeling like something is in your eyes
 - eye irritation
 - eye pain

Trademarks are owned by or licensed to the GSK group of companies.

GSK

©2025 GSK or licensor.
PMUS-BLMLBND250018 October 2025
Produced in USA.

File Name: Patient Education Brochure



BLENREP
belantamab
mafodotin-blmf
for injection 70 mg